Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

Cancer Cell

Volumn 24, Issue 1, 2013, Pages 120-129

  Vaillant, François ^a,b   Merino, Delphine ^a,b   Lee, Lily ^a,b   Breslin, Kelsey ^a   Pal, Bhupinder ^a,b   Ritchie, Matthew E ^a,c   Smyth, Gordon K ^a,c   Christie, Michael ^a,b,d   Phillipson, Louisa J ^a,b   Burns, Christopher J ^a,b   Mann, G Bruce ^b,e   Visvader, Jane E ^a,b   Lindeman, Geoffrey J ^a,b,d  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 199; ANTINEOPLASTIC AGENT; AZD 8055; BH3 PROTEIN; BIM PROTEIN; CASPASE 3; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PKI 587; PROTEIN BCL 2; PROTEIN BCL XL; RAPAMYCIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ENDOMETRIAL THICKNESS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

MAMMALIA;

EID: 84880028368     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.06.002     Document Type: Article

References (39)

1. Abdel-Fatah T.M., Powe D.G., Ball G., Lopez-Garcia M.A., Habashy H.O., Green A.R., Reis-Filho J.S., Ellis I.O. Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J.Pathol. 2010, 222:388-399.
2. Ali H.R., Dawson S.J., Blows F.M., Provenzano E., Leung S., Nielsen T., Pharoah P.D., Caldas C. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J.Pathol. 2012, 226:97-107.
3. Burstein H.J., Prestrud A.A., Seidenfeld J., Anderson H., Buchholz T.A., Davidson N.E., Gelmon K.E., Giordano S.H., Hudis C.A., Malin J., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J.Clin. Oncol. 2010, 28:3784-3796. American Society of Clinical Oncology.
4. Calza S., Hall P., Auer G., Bjöhle J., Klaar S., Kronenwett U., Liu E.T., Miller L., Ploner A., Smeds J., et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006, 8:R34.
5. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J.Biol. Chem. 2001, 276:9817-9824.
6. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
7. Certo M., Del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 9:351-365.
8. Chen J., Jin S., Abraham V., Huang X., Liu B., Mitten M.J., Nimmer P., Lin X., Smith M., Shen Y., et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents invitro and invivo. Mol. Cancer Ther. 2011, 10:2340-2349.
9. Cory S., Huang D.C., Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
10. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.
11. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
12. Davids M.S., Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J.Clin. Oncol. 2012, 30:3127-3135.
13. Davids M.S., Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell 2013, 23:139-141.
14. Dawson S.J., Makretsov N., Blows F.M., Driver K.E., Provenzano E., Le Quesne J., Baglietto L., Severi G., Giles G.G., McLean C.A., et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br. J. Cancer 2010, 103:668-675.
15. Del Gaizo Moore V., Brown J.R., Certo M., Love T.M., Novina C.D., Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J.Clin. Invest. 2007, 117:112-121.
16. DeRose Y.S., Wang G., Lin Y.C., Bernard P.S., Buys S.S., Ebbert M.T., Factor R., Matsen C., Milash B.A., Nelson E., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 2011, 17:1514-1520.
17. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5:671-688.
18. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.J. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 2011, 22:1736-1747. Panel members.
19. Green D.R., Walczak H. Apoptosis therapy: driving cancers down the road to ruin. Nat. Med. 2013, 19:131-133.
20. Hui L., Rodrik V., Pielak R.M., Knirr S., Zheng Y., Foster D.A. mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J. Biol. Chem. 2005, 280:35829-35835.
21. Laidlaw I.J., Clarke R.B., Howell A., Owen A.W., Potten C.S., Anderson E. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 1995, 136:164-171.
22. Lam L., Hu X., Aktary Z., Andrews D.W., Pasdar M. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha. Breast Cancer Res. Treat. 2009, 118:605-621.
23. Landis M.D., Lehmann B.D., Pietenpol J.A., Chang J.C. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res. 2013, 15:201.
24. Lindeman G.J., Visvader J.E. Targeting BCL-2 in breast cancer: exploiting a tumor lifeline to deliver a mortal blow?. Breast Cancer Manage. 2013, 2:1-4.
25. Mason K.D., Carpinelli M.R., Fletcher J.I., Collinge J.E., Hilton A.A., Ellis S., Kelly P.N., Ekert P.G., Metcalf D., Roberts A.W., et al. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
26. Mérino D., Khaw S.L., Glaser S.P., Anderson D.J., Belmont L.D., Wong C., Yue P., Robati M., Phipson B., Fairlie W.D., et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012, 119:5807-5816.
27. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., Gao S., Mills G.B., Brugge J.S. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
28. Nasu K., Nishida M., Kawano Y., Tsuno A., Abe W., Yuge A., Takai N., Narahara H. Aberrant expression of apoptosis-related molecules in endometriosis: a possible mechanism underlying the pathogenesis of endometriosis. Reprod. Sci. 2011, 18:206-218.
29. Ni Chonghaile T., Sarosiek K.A., Vo T.T., Ryan J.A., Tammareddi A., Moore Vdel.G., Deng J., Anderson K.C., Richardson P., Tai Y.T., et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011, 334:1129-1133.
30. Oakes S.R., Vaillant F., Lim E., Lee L., Breslin K., Feleppa F., Deb S., Ritchie M.E., Takano E., Ward T., et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc. Natl. Acad. Sci. USA 2012, 109:2766-2771.
31. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
32. Pérez-Tenorio G., Stål O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 2002, 86:540-545. Southeast Sweden Breast Cancer Group.
33. Polyak K., Metzger Filho O. SnapShot: breast cancer. Cancer Cell 2012, 22:562-562.e1.
34. Puglisi M., van Doorn L., Blanco-Codesido M., De Jonge M.J., Moran K., Yang J., Busman T., Franklin C., Mabry M., Krivoshik A., et al. A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors. J.Clin. Oncol. 2011, 29. Suppl abstract 2518.
35. Roberts A.W., Seymour J.F., Brown J.R., Wierda W.G., Kipps T.J., Khaw S.L., Carney D.A., He S.Z., Huang D.C., Xiong H., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J.Clin. Oncol. 2012, 30:488-496.
36. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., Dayton B.D., Ding H., Enschede S.H., Fairbrother W.J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19:202-208.
37. Strasser A., Cory S., Adams J.M. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011, 30:3667-3683.
38. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., Johnson E.F., Marsh K.C., Mitten M.J., Nimmer P., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
39. Vandenberg C.J., Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has invivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013, 121:2285-2288.